QMMM Holdings Ltd (QMMM): I expect it breaks the $1 today.

Play Episode

11min

Proactive - Interviews for investors

Immunic CMO discusses significance of MS Awareness Month; progress with treatment

Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler talked with Proactive's Stephen Gunnion about the company’s work in multiple sclerosis (MS) as MS Awareness Month concludes. Muehler discussed the importance of continued research funding and the community’s role in advancing treatment. He highlighted the company’s lead asset, vidofludimus calcium, which is in advanced-stage clinical trials. Results from the phase 2 EMPHASIS trial in relapsing-remitting MS showed a reduction of about three-quarters of new MRI lesions compared to placebo. Muehler said, “This is a very good value,” and pointed to biomarker data showing a strong, dose-linear suppression of neurofilament — a sign of nerve cell damage. A phase 3 program involving more than 2,000 patients is now underway, with data expected in 2026. In progressive MS, Immunic is close to reporting data from its phase 2 CALLIPER trial, having already seen positive biomarker signals at 24 weeks. Muehler addressed patients’ fears of disability, stressing the company’s commitment to tackling "progression independent of relapse activity (PIRA)", a key unmet need. He emphasized vidofludimus calcium’s dual mechanism — both anti-inflammatory and neuroprotective — and its potential to become the first oral drug targeting the full spectrum of MS. To hear more insights from Immunic and other biotech leaders, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and enable notifications for future content. #ImmunicTherapeutics #MultipleSclerosis #MSAwarenessMonth #vidofludimuscalcium #MSTreatment #ClinicalTrials #Neuroprotection #MSResearch #BiotechNews #ProgressiveMS #RelapsingMS #PIRA #DrugDevelopment

Proactive - Interviews for investors

Inspired PLC CEO Mark Dickinson breaks down FY24 highlights, net zero strategy

Inspired PLC (AIM:INSE) chief executive Mark Dickinson takes Proactive's Stephen Gunnion through the company's 2024 financial results, its ongoing mission to help clients reach net zero, and the outlook for 2025. Dickinson provided an overview of the group’s four complementary divisions: software, assurance, ESG, and optimisation. These work together to help Inspired’s B2B clients manage energy costs, comply with ESG reporting obligations, and implement real carbon reduction strategies. “The backdrop continues to be increasingly favourable for Inspired as we help those clients navigate their way through those challenges,” Dickinson said, citing continuing demand despite lower energy prices. FY24 was a year focused on strengthening the balance sheet. Dickinson said the company eliminated all contingent consideration liabilities, raised capital, and reduced net leverage from 2.59x to 1.47x adjusted EBITDA—giving the business a firmer platform for growth. The company’s non-financial KPIs also moved in a positive direction, with cross-selling increasing and more than 50% of optimisation clients returning for additional services. Inspired is now serving 420 clients with optimisation support. Looking ahead, Dickinson said trading in 2025 started in line with expectations, and the business is progressing well on previously delayed projects. He remains optimistic about the pipeline and demand drivers, particularly in energy conservation, ESG compliance, and net zero support. For more CEO interviews and company updates, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe, and enable notifications so you never miss an update. #InspiredPLC #NetZero #EnergyEfficiency #ESG #CarbonReduction #SustainabilityGoals #CleanEnergy #GreenBusiness #UKStocks #ProactiveInvestors

Proactive - Interviews for investors

Candel Therapeutics shares positive survival data for investigational immunotherapy in NSCLC

Candel Therapeutics CEO Dr. Paul Peter Tak joined Steve Darling from Proactive to announce final survival data from a Phase 2a clinical trial evaluating the company’s investigational immunotherapy in patients with stage III/IV non-small cell lung cancer (NSCLC) who had an inadequate response to immune checkpoint inhibitor (ICI) treatment. The study reported a median overall survival (mOS) of 24.5 months in 46 evaluable patients who received two courses of the investigational therapy. In a subset of patients who had progressive disease at baseline despite ICI treatment, mOS was 21.5 months. Historically, similar patients receiving standard-of-care chemotherapy have had mOS between 9.8 and 11.8 months, with published studies rarely exceeding 12 months. With a median follow-up of 32.4 months, the data demonstrated long-term survival benefits, with 37% of patients who had progressive disease despite ICI therapy still alive two years after treatment. Based on these positive results, Candel Therapeutics will continue advancing the development program, including preparations for a potential registrational trial in patients with non-squamous histology NSCLC. The U.S. Food and Drug Administration (FDA) has previously granted Fast Track Designation for the investigational therapy in combination with an antiviral agent and ICI therapy for patients with stage III/IV NSCLC who are resistant to first-line PD-(L)1 inhibitors and do not have activating molecular driver mutations or have progressed on targeted therapy. These findings support the therapy’s potential as a new treatment option for NSCLC patients with limited alternatives. #proactiveinvestors #candeltherapeuticsinc #nasdaq #cadl #CancerTreatment #ViralTherapy #ProstateCancer #PancreaticCancer #Glioblastoma #PaulPeterTak #ClinicalTrials #BiotechNews #Immunotherapy #Oncology #CancerResearch

Proactive - Interviews for investors

VSPC expansion plans detailed by Livium CEO

Livium Ltd CEO Simon Linge talked with Proactive about the company's progress on its lithium ferro phosphate (LFP) demonstration plant and strategic growth plans. The company is working to secure the remaining A$30.00 million to fully fund the plant, with Linge stating that the process involves "complex transactions" and that "there's a bit to be thought through". The funding includes support from a substantial A$30.00 million grant from the Australian Renewable Energy Agency (ARENA), which covers around 50% of the facility’s estimated build and operational costs. Linge said the grant acts as both financial support and validation of Livium’s VSPC technology, which is positioned as leading-edge and referred to in China as Generation 4 LFP. He highlighted that demand from potential customers already exceeds the plant’s expected capacity, and the company is selectively targeting energy storage and electric vehicle sectors. In the US, Livium is working closely with distributor United Mineral & Chemical Corporation (UMC), which has already introduced the business to new clients and OEMs. Linge said UMC's presence provides "boots on the ground" support, crucial for US market penetration. The company continues to evaluate whether to expand through licensing or direct operations, based on proximity to clients and local market conditions. 📺 For more insightful interviews, visit [Proactive's YouTube channel](https://www.youtube.com/@ProactiveInvestors). Don’t forget to like this video, subscribe to the channel, and enable notifications for future updates. #Livium #VSPC #LithiumIronPhosphate #BatteryMaterials #EnergyStorage #EVBatteries #ARENAgrant #CleanEnergy #TechInnovation #ProactiveInvestors

Followers	60
Posts	7253
Boards Moderated	0
Alias Born	11/29/2010

Volume:	100,981
Day Range:	0.80 - 0.8928
Bid:	0.80
Ask:	0.90
Last Trade Time:	6:49:12 PM EDT
Total Trades:	221

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

QMMM Detailed Quote

Recent QMMM News

More QMMM News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent QMMM News

Go Ad-Free